Management of Cardiac Complications in Hematologic Malignancies

Cardiac involvement in hematologic malignancies may stem from the disease process or systemic therapy regimen. Chemotherapy-related cardiotoxicity was historically classified into Type I and Type II, irreversible and reversible cardiac dysfunction, respectively. Modern anti-cancer therapies have expanded this classification system and complications continue to come to light. Continued education for oncology care providers is necessary to promote awareness of the cardiac effects of hematologic malignancies and their treatment so that effective methods of management may be implemented.

This information was originally presented at the NCCN 2020 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ held on October 8, 2020.

Target Audience

This educational program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Outline the key features of at least three cardiac toxicities pertinent to practice with patients having hematologic malignancies.
  • Describe methods of minimizing the risk for cardiotoxicity with patients having hematologic malignancies.
  • In a given case scenario of an individual at risk or experiencing potential cardiac toxicities, define the priority interventions.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer Inc.

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Sanofi Genzyme
Course summary
Available credit: 
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
10/30/2020
Course expires: 
10/30/2021
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2020 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

Brenda Shelton, DNP, APRN-CNS, CCRN, AOCN
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Brenda Shelton, DNP, APRN-CNS, CCRN, AOCN

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Michael Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Leadership listed below discloses no relevant financial relationships: 

Robert W. Carlson, MD; Gary J. Weyhmuller, MBA, SPHR 

The NCCN Leadership listed below discloses the following relevant financial relationships: 

Wui-Jin Koh, MD: IBM Watson Health for Oncology and Genomics; Scientific Advisor

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Giby V. George, MD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hours.

Available Credit

  • 0.75 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: